As a precautionary measure, the Medicines and Healthcare products Regulatory Agency (MHRA) has updated it’s guidance for healthcare professionals who manage patients implanted with metal-on-metal hip replacements.
This updated guidance replaces the previous advice provided in 2012 which was issued to ensure monitoring for soft-tissue reactions.
The key changes include additional recommendations regarding the monitoring of patients which have been designed to ensure longer term followup is undertaken for all patients with these implants.
Dr Neil McGuire MHRA’s Clinical Director of Medical Devices said:
“We have updated the current advice to ensure patients with metal on metal hip implants continue to receive appropriate follow up to detect emerging complications should they arise.”